A contraceptive implant does not suddenly stop working the instant its labeled expiration date passes, but pregnancy risk does increase over time beyond that date. The expiration printed on the packaging reflects the window the manufacturer tested and regulators approved, not a biological on-off switch. Hormone levels inside the rod decline gradually over years, and research suggests meaningful contraceptive protection can persist for a year or two past the official end date for many people. That said, the margin of safety narrows, and your individual risk depends on factors like body weight and medications you take.
How the Implant Prevents Pregnancy
The implant is a small, flexible rod inserted under the skin of your upper arm. It releases a steady, low dose of a synthetic progestin into your bloodstream. That hormone works on multiple fronts: it thickens cervical mucus so sperm have a much harder time reaching an egg, and it partially or completely suppresses the hormonal surge that triggers ovulation. Changes to the uterine lining also occur, though exactly how much that contributes to contraception is hard to pin down.1PubMed. Mechanisms that explain the contraceptive action of progestin implants for women The key point is that the implant relies on maintaining a certain concentration of hormone in your blood. When that concentration drops below a critical threshold, ovulation can resume, and pregnancy becomes possible.
What the Expiration Date Actually Means
The most widely used implant today, the etonogestrel implant (sold as Nexplanon in the United States), is FDA-approved for three years. Older levonorgestrel-based implants like Jadelle were approved for five years, and the original six-capsule Norplant system was also approved for five. These timelines reflect how long manufacturers ran their pivotal clinical trials, not the moment the hormone runs dry. Within the approved window, efficacy is remarkably high. In a three-year trial of the etonogestrel implant, not a single pregnancy occurred among over 300 users while the device was in place.2PubMed. Nexplanon, a radiopaque etonogestrel implant in combination with a next-generation applicator: 3-year results of a noncomparative multicenter trial Across the broader literature on progestin implants, five-year pregnancy rates sit below about 1.5 per 100 users.3PubMed. Implantable contraceptives for women: effectiveness, discontinuation rates, return of fertility, and outcome of pregnancies
So during the approved lifespan, the implant is one of the most effective contraceptives available. The question everyone wants answered is what happens after that window closes.
Evidence for Continued Protection Beyond the Approved Date
Several studies have followed implant users past the official expiration, and the results are reassuring, though not unlimited. A study that tracked over 200 women using the etonogestrel implant for a full five years found zero pregnancies during the two additional years beyond the three-year approval. The cumulative five-year pregnancy rate was about 0.6 per 100 woman-years, which is still extremely low and statistically comparable to the levonorgestrel implant used over the same period.4PubMed Central. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant The Society of Family Planning has acknowledged this evidence, noting that extended use of long-acting reversible contraceptives beyond FDA-approved durations can be a safe and effective option for many patients, while recommending that clinicians discuss effectiveness with patients individually.5PubMed. Society of Family Planning clinical recommendation: Extended use of long-acting reversible contraception
For levonorgestrel implants, the data stretches even further. Annual pregnancy rates for Norplant users stayed below 1 per 100 women through seven continuous years of use, two years past its five-year approval.6PubMed. Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants This does not mean the implant is equally protective in year seven as in year one. It means the residual hormone, while declining, remained high enough to prevent pregnancy in the vast majority of users studied.
That said, the overall quality of the extended-use research is limited. A systematic review identified only six studies meeting its criteria for evaluating implant efficacy beyond approved durations, and most were small, prospective cohort studies rather than large randomized trials.7PubMed Central. Systematic review of efficacy with extending contraceptive implant duration The evidence is encouraging but thinner than what underpins the approved lifespan.
Why Hormone Levels Matter More Than the Calendar
The real question behind the expiration date is whether enough hormone remains in your blood to suppress ovulation. Researchers have measured this directly. For the etonogestrel implant, median blood levels of the hormone were about 208 pg/mL at the three-year expiration mark, dropping to roughly 166 pg/mL at the end of four years and 153 pg/mL at the end of five years. The threshold generally considered necessary to suppress ovulation is around 90 pg/mL, and median levels stayed well above that line through year five across all body mass index categories studied.8PubMed Central. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration At three and four years specifically, levels did not differ significantly by BMI.9PubMed Central. Use of the Etonogestrel Implant and Levonorgestrel Intrauterine Device Beyond the U.S. Food and Drug Administration–Approved Duration
Levonorgestrel implants show a similar slow decline. In a seven-year study of Jadelle users, mean levonorgestrel levels started at 435 pg/mL at one month and fell to about 224 pg/mL by year seven, roughly half the starting value. Pregnancies that did occur during use happened in women whose last measured levels were at or below 180 pg/mL. By years six and seven, about a third of blood samples fell below that 180 pg/mL mark, suggesting that the safety margin narrows considerably in those later years, especially for heavier users.10PubMed. Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants
The takeaway is that hormone release is a slow fade, not a cliff. But “above the ovulation threshold on average” is not the same as “safe for everyone.” Medians are averages: some people will be well above the threshold, while others will be closer to or below it. The further past expiration you go, the more people fall into the risk zone.
Body Weight and the Margin of Safety
One persistent concern is whether the implant works as well in people who weigh more, since a larger body volume could dilute the circulating hormone. The clinical evidence is more reassuring than you might expect, at least within the approved duration. A systematic review of etonogestrel implant use in people with overweight and obesity found that among nine publications, no pregnancies were reported in users with a BMI between 25 and 30. In users with obesity (BMI 30 and above), two studies reported one pregnancy each, with failure rates of 0.02 and 0.23 per 100 woman-years, both still well under 1 per 100.11BMJ Sexual & Reproductive Health. Effectiveness of the etonogestrel subdermal implant in users with overweight and obesity: a systematic literature review Interestingly, the three pregnancies that did occur during the approved window happened in people with a BMI under 25.12PubMed Central. Contraceptive Failure Rates of Etonogestrel Subdermal Implants in Overweight and Obese Women
Still, blood levels of etonogestrel do run lower in people with higher body weight. One pharmacokinetic study found levels in obese women were 31 to 63 percent lower than in normal-weight women over time, though the differences did not reach statistical significance and levels still appeared adequate to prevent ovulation.13American Journal of Obstetrics and Gynecology. Pharmacokinetics of the etonogestrel contraceptive implant in obese women The practical worry is that if your baseline levels are already lower, the ongoing decline with time could push you below the protective threshold sooner. If you have a higher BMI and your implant is past its date, the margin of safety is likely thinner than it would be for someone who weighs less.
Drug Interactions That Speed Up Hormone Breakdown
Certain medications can slash the amount of active hormone in your blood by speeding up the liver enzymes that metabolize it. The progestins in implants are broken down by an enzyme called CYP3A4, and drugs that ramp up that enzyme’s activity can reduce hormone levels enough to risk an unintended pregnancy.14PubMed. Pharmacokinetic Approach of Clinically Important Drug Interactions of Hormonal Contraceptives – A Review The most well-known culprits are certain anti-seizure medications (like carbamazepine and phenytoin), the tuberculosis drug rifampin, and the HIV medication efavirenz.
Efavirenz, an antiretroviral used in many HIV treatment regimens, is a particularly well-studied example. Pharmacokinetic modeling found that efavirenz cut simulated levonorgestrel levels by roughly 50 percent compared to women not taking the drug. Even at a lower 400 mg dose of efavirenz, the reduction was similar.15Journal of Antimicrobial Chemotherapy. Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART When the hormone dose in the implant was increased to compensate, levels were restored to the expected range, suggesting the interaction is about metabolism speed, not an outright block of the drug’s action.
If you are taking any enzyme-inducing medication, the effective lifespan of your implant could be considerably shorter than the label suggests, and using it past the approved date would carry even higher risk. This is one area where talking to your prescriber is genuinely important rather than just a boilerplate recommendation.
How Fast Fertility Returns After Removal
If you are wondering whether an expired implant delays your ability to get pregnant once you finally have it removed, the answer is no. Fertility bounces back quickly regardless of how long you used the device. In a study of women who had levonorgestrel implants removed specifically to conceive, 20 percent became pregnant within the first month. By six months, the pregnancy rate was about 63 percent, and by one year it reached 80 percent.16PubMed. Return of fertility following discontinuation of Norplant-II subdermal implants Those numbers are essentially what you’d expect for any population trying to conceive, which is the point: the implant does not cause lasting changes to fertility.
Ovulation itself tends to resume within three to four weeks of etonogestrel implant removal.17European journal of contraception & reproductive health care. The pharmacokinetics and pharmacodynamics of Implanon®, a single-rod etonogestrel contraceptive implant Age does have a modest effect: women over 30 in the removal study had a median time to conception of six months, versus about four months for women under 30. But by two years, pregnancy rates converged at nearly 90 percent regardless of age. So if your implant has expired and you want to get pregnant, removing it promptly puts you on a normal fertility timeline.
Conversely, if your implant has expired and you do not want to get pregnant, that rapid return of fertility is exactly the reason you should not wait too long. Ovulation can resume while the rod is still in your arm if hormone levels have dropped far enough.
Ectopic Pregnancy and Other Rare Complications
When a pregnancy does occur during implant use, whether within or beyond the approved window, there is a question about whether it is more likely to be ectopic, meaning the embryo implants outside the uterus. Progestin-only methods slow the movement of an egg through the fallopian tubes, and there has been theoretical concern that this could raise ectopic risk if the method fails. A systematic review found that among levonorgestrel implant studies, the incidence of ectopic pregnancy ranged from 0 to about 2.9 per 1,000 woman-years. Studies of the etonogestrel implant reported very few ectopic pregnancies overall.18Contraception. Ectopic pregnancy with use of progestin-only injectables and contraceptive implants: a systematic review Because implant failure is so rare in the first place, the absolute number of ectopic pregnancies is very small. But if you have an expired implant and develop symptoms of pregnancy (missed period, pelvic pain, unusual bleeding), getting evaluated promptly matters, since ectopic pregnancy can be a medical emergency.
Practical Guidance If Your Implant Is Past Its Date
Life gets busy, and many people end up keeping their implant a few months or even a year past the official replacement date. Here is what the evidence suggests for your real-world decision-making:
- A few months past: For the etonogestrel implant, hormone levels at three years are still well above the ovulation-suppression threshold for most people. A short delay in getting it replaced is unlikely to put you at meaningful risk, though the protective margin is not as large as it was in year one.
- One to two years past: The extended-use data showing zero pregnancies through five years of etonogestrel implant use is reassuring, but individual variation in hormone levels grows wider over time. If you have a higher body weight or take enzyme-inducing medications, your margin may already be slim. Using a backup method like condoms is a reasonable precaution.
- More than two years past: Evidence gets thin here for the etonogestrel implant specifically. For levonorgestrel implants used past year five, about a third of users had hormone levels below the pregnancy-risk threshold by years six and seven. Relying on an implant this far past its date without backup protection is a gamble with rising odds against you.
The most straightforward step is to schedule a replacement. The removal-and-reinsertion process is quick, typically taking only a few minutes in a clinic visit, and the new implant starts working immediately if placed on the same day. If you cannot get in right away, adding a barrier method in the meantime is a sensible hedge.
Why the FDA Label Is Conservative
You might wonder why the label says three years if the evidence supports longer use. Regulatory approval is tied to the data the manufacturer submits, and the pivotal trials for the etonogestrel implant were designed around a three-year endpoint. Getting an extended approval would require running or funding additional large trials specifically to demonstrate safety and efficacy for a longer period, and there is limited financial incentive for a manufacturer to do so when the current label already supports the product. The gap between what the research community knows and what the label says is a familiar pattern with many long-acting medications and devices.
Clinicians are aware of this gap. The Society of Family Planning’s clinical recommendation explicitly acknowledges that extended use can be appropriate and encourages individualized discussion between providers and patients.5PubMed. Society of Family Planning clinical recommendation: Extended use of long-acting reversible contraception So if your provider tells you it is safe to keep your implant a bit longer while you arrange a replacement, that advice is grounded in real data, not just a casual guess.
When the Implant Actually Fails Before It Expires
Most conversations about implant failure focus on expiration, but rare failures can happen within the approved window too. The most common culprit is not a hormonal shortfall but a problem with insertion: if the rod is not placed deeply enough, it can migrate or be expelled without the user noticing. Drug interactions, as described above, are another route to premature failure. And very occasionally, a pregnancy occurs despite apparently adequate hormone levels, for reasons that remain unexplained.
Within the approved three-year period, the etonogestrel implant’s failure rate is essentially zero in clinical trials. The single pregnancy observed in one large study of over 1,300 woman-years happened in a participant with obesity, but the overall failure rate did not differ significantly by BMI.12PubMed Central. Contraceptive Failure Rates of Etonogestrel Subdermal Implants in Overweight and Obese Women In real-world use, where insertion errors and drug interactions are possible, the rate is slightly higher than in controlled trials, but the implant still outperforms nearly every other reversible contraceptive method.